INT96851

From wiki-pain
Revision as of 02:54, 24 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 5.98
Pain Relevance 4.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CCL2) extracellular space (CCL2) aging (CCL2)
extracellular region (CCL2) cell adhesion (CCL2) cytoskeleton organization (CCL2)
Anatomy Link Frequency
endothelial cells 4
plasma 2
monocytes 2
PSC 2
CCL2 (Homo sapiens)
Pain Link Frequency Relevance Heat
ischemia 9 100.00 Very High Very High Very High
aspirin 6 99.42 Very High Very High Very High
dexamethasone 87 98.72 Very High Very High Very High
Cannabinoid receptor 36 98.36 Very High Very High Very High
Bioavailability 1 98.28 Very High Very High Very High
chemokine 34 96.32 Very High Very High Very High
Inflammation 168 96.16 Very High Very High Very High
cytokine 132 95.92 Very High Very High Very High
adenocard 9 93.08 High High
Cannabinoid 52 91.32 High High
Disease Link Frequency Relevance Heat
Cv Unclassified Under Development 9 100.00 Very High Very High Very High
Glioma 50 99.84 Very High Very High Very High
Cancer 109 99.56 Very High Very High Very High
Primary Sclerosing Cholangitis 88 99.14 Very High Very High Very High
INFLAMMATION 186 96.16 Very High Very High Very High
Apoptosis 29 89.64 High High
Hyperhomocysteinemia 2 86.80 High High
Adhesions 17 84.16 Quite High
Necrosis 9 83.96 Quite High
Pancreatitis 64 83.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Forskolin, a direct stimulator of adenylyl cyclase, decreased the interleukin (IL)-1beta-induced eotaxin and MCP-1 release by 73+/-8 and 65+/-6%, respectively. 8Bromo-cAMP, a cAMP analogue, similarly decreased the chemokine production by 58+/-9 and 63+/-8% for eotaxin and MCP-1, respectively.
Negative_regulation (decreased) of Localization (release) of MCP-1 associated with chemokine
1) Confidence 0.53 Published 2003 Journal Eur. Respir. J. Section Abstract Doc Link 12952251 Disease Relevance 0.24 Pain Relevance 0.22
H-89, an inhibitor of PKA, was able to inhibit the decrease in eotaxin and MCP-1 protein release induced by forskolin.
Negative_regulation (inhibit) of Localization (release) of MCP-1
2) Confidence 0.53 Published 2003 Journal Eur. Respir. J. Section Abstract Doc Link 12952251 Disease Relevance 0.18 Pain Relevance 0.24
The results showed that (i) aspirin, fenofibrate and clofibrate decrease significantly the MCP-1 expression and secretion in human endothelial cells; (ii) the high glucose up-regulated expression of MCP-1 in endothelial cells was significantly reduced by inhibitors of NF-kB and reactive oxygen species; (iii) all drugs notably decrease the level of the reactive oxygen species and activation of NF-kB and AP-1.
Negative_regulation (decrease) of Localization (secretion) of MCP-1 in endothelial cells associated with aspirin
3) Confidence 0.41 Published 2006 Journal Vascul. Pharmacol. Section Abstract Doc Link 16600694 Disease Relevance 0.41 Pain Relevance 0.34
H-89, an inhibitor of PKA, was able to inhibit the decrease in eotaxin and MCP-1 protein release induced by forskolin.
Negative_regulation (decrease) of Localization (release) of MCP-1
4) Confidence 0.39 Published 2003 Journal Eur. Respir. J. Section Abstract Doc Link 12952251 Disease Relevance 0.18 Pain Relevance 0.24
resp.) while fetal MCP-1 concentrations were significantly lower
Negative_regulation (lower) of Localization (concentrations) of MCP-1
5) Confidence 0.37 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234089 Disease Relevance 0.06 Pain Relevance 0.06
resp.) while fetal MCP-1 concentrations were significantly lower
Negative_regulation (lower) of Localization (concentrations) of MCP-1
6) Confidence 0.37 Published 2007 Journal Mediators of Inflammation Section Body Doc Link PMC2234089 Disease Relevance 0.08 Pain Relevance 0.15
The immunosuppressant cyclosporin A (50 microM) partially reduced the ischemia-stimulated IL-8 and MCP-1 secretion by HCEC.
Negative_regulation (reduced) of Localization (secretion) of MCP-1 in HCEC associated with ischemia
7) Confidence 0.35 Published 2000 Journal Acta Neurochir. Suppl. Section Abstract Doc Link 11450070 Disease Relevance 1.15 Pain Relevance 0.60
These experiments demonstrated that IL-6 and MCP-1 secretion were significantly reduced by WIN (p?
Negative_regulation (reduced) of Localization (secretion) of MCP-1
8) Confidence 0.23 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2253501 Disease Relevance 0.58 Pain Relevance 0.21
Homocysteine also limits the bioavailability of nitric oxide, and in cultured human aortic endothelial cells and THP-1 monocytes, decreases the expression and secretion of MCP-1 [7,38].
Negative_regulation (decreases) of Localization (secretion) of MCP-1 in monocytes associated with bioavailability
9) Confidence 0.21 Published 2008 Journal Archives of Drug Information Section Body Doc Link PMC2817441 Disease Relevance 0.36 Pain Relevance 0.31
As TMZ can reduce CCL2 secretion by glioma tumour cells, this could augment indirectly the efficacy of immunotherapy [83, 84].
Negative_regulation (reduce) of Localization (secretion) of CCL2 associated with cancer and glioma
10) Confidence 0.19 Published 2010 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2952949 Disease Relevance 1.23 Pain Relevance 0.03
Activation of cannabinoid receptors, however, induced de-activation of PSC and dose-dependently inhibited growth and decreased IL-6 and MCP-1 secretion as well as fibronectin, collagen1 and alphaSMA levels.
Negative_regulation (decreased) of Localization (secretion) of MCP-1 in PSC associated with cannabinoid receptor and primary sclerosing cholangitis
11) Confidence 0.17 Published 2008 Journal PLoS ONE Section Abstract Doc Link PMC2253501 Disease Relevance 1.20 Pain Relevance 1.02
In addition, there was a greater inhibition of MCP-1 release by BOL-303242-X as compared to DEX at 10 µM (Figure 1).
Negative_regulation (inhibition) of Localization (release) of MCP-1 associated with dexamethasone
12) Confidence 0.12 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2790480 Disease Relevance 0.15 Pain Relevance 0.61
BOL-303242-X significantly inhibited G-CSF, IL-6, IL-8, and MCP-1 release from HConFs at doses of 1–100 nM in a dose-dependent manner (Figure 1).
Negative_regulation (inhibited) of Localization (release) of MCP-1
13) Confidence 0.12 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2790480 Disease Relevance 0 Pain Relevance 0.55
The improvement of angina pectoris symptoms and electrocardiogram (ECG) was observed after 2 weeks of treatment and the levels of plasma CRP, IL-6, TNF-alpha and MCP-1 were measured before and after treatment.
Negative_regulation (measured) of Localization (levels) of MCP-1 in plasma
14) Confidence 0.08 Published 2008 Journal Zhongguo Zhong Xi Yi Jie He Za Zhi Section Body Doc Link 18672762 Disease Relevance 0.17 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox